Bugs & Drugs

I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens (just below) and pipeline reviews. Note in particular that a comparative Summary of the priority pathogens lists is provided. For my summary of incentives to support this pipeline, see this webpage. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • By my count, six priority pathogen lists have been proposed / published to date:
    1. WHO 2022 Fungal PPL: Newsletter is here, report is here.
    2. India 2021: Newsletter is here, report is here.
    3. CDC 2019: Newsletter is here, report itself is here.
    4. WHO 2017: Newsletter is here, report itself is here.
    5. CDC 2013: Report itself is here.
    6. ESKAPE list 2008-9: This is the grandfather/mother of them all! The original papers are here:
      • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
      • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12

To help you keep them organized, a comparative summary of the priority pathogen lists (including the 2022 WHO fungal PPL) as a PowerPoint deck is here.

  • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.

Pipeline Reviews (therapeutic products, unless otherwise noted)

  • Reviews by WHO
    • WHO 2022 review of preclinical and clinical vaccines (data cut-off not stated, appears to be from 2010 forward). Here are links to the report, a press release, and a newsletter about the report.
    • WHO 2022 (data cut-off 30 June 2021): My newsletter is here and the review itself is here. See also Butler et al., https://journals.asm.org/doi/10.1128/aac.01991-21) and this 17 Jan 2022 newsletter.
    • WHO 2020 (data cut-off 1 Sep 2020): My newsletter is here (and includes a video chat with Peter Beyer, one of the key drivers of the report). The review itself is here.
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of March 2021; see also this newsletter)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2020.
    • Non-traditional products are separately summarized here.
  • Independent pipeline reviews
  • Access- and Stewardship-focused reviews
    • CDDEP’s “The State of the World’s Antibiotics Report in 2021” (link) presents extensive data on global antimicrobial use and resistance, a brief pipeline review, and by-country dashboards
    • ATMF’s “2021 Access to Medicine Index” (link) summarizes progress made and work to be done on access.

NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Scroll to Top